Several distinct strategies are being explored to enhance the sensitivity of GC/GEJC to PD‐1/PD‐L1 inhibitors, largely by modulating the tumor immune microenvironment and overcoming resistance pathways. This evidence concerns the gene CD274 and gastric cancer.